Errazquin R., Page A., Suñol A., Segrelles C., Carrasco E., Peral J., Garrido-Aranda A., Del Marro S., Ortiz J., Lorz C., Minguillon J., Surralles J., Belendez C., Alvarez M., Balmaña J., Bravo A., Ramirez A., Garcia-Escudero R.. Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia. ORAL ONCOLOGY. 2022; 134DOI:10.1016/j.oraloncology.2022.106184. PMID:36191479. IF:4.800(Q1/1D).

Sevilla, J, Navarro, S, Rio, P, Sanchez-Dominguez, R, Zubicaray, J, Galvez, E, Merino, E, Sebastian, E, Azqueta, C, Casado, JA, Segovia, JC, Alberquilla, O, Bogliolo, M, Roman-Rodriguez, FJ, Gimenez, Y, Larcher, L, Salgado, R, Pujol, RM, Hladun, R, Castillo, A, Soulier, J, Querol, S, Fernandez, J, Schwartz, J, de Andoin, NG, Lopez, R, Catala, A, Surralles, J, Diaz-de-Heredia, C, Bueren, JA. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy-Methods & Clinical Development. 2021; 22DOI:10.1016/j.omtm.2021.06.001. PMID:34485595. IF:5.849(Q2/4D).

Castells-Roca, L, Gutierrez-Enriquez, S, Bonache, S, Bogliolo, M, Carrasco, E, Aza-Carmona, M, Montalban, G, Munoz-Subirana, N, Pujol, R, Cruz, C, Llop-Guevara, A, Ramirez, MJ, Saura, C, Lasa, A, Serra, V, Diez, O, Balmana, J, Surralles, J. Clinical consequences of BRCA2 hypomorphism. npj Breast Cancer. 2021; 7(1)DOI:10.1038/s41523-021-00322-9. PMID:34504103. IF:7.519(Q1/3D).

Isla, D, de Castro, J, Garcia-Campelo, R, Majem, M, Vicente, D, Juan-Vidal, O. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical & Translational Oncology. 2021; 23(7)DOI:10.1007/s12094-020-02518-0. PMID:33210237. IF:3.340(Q3/7D).

Garcia-Alfonso, P, Saiz-Rodriguez, M, Mondejar, R, Salazar, J, Paez, D, Borobia, AM, Safont, MJ, Garcia-Garcia, I, Colomer, R, Garcia-Gonzalez, X, Herrero, MJ, Lopez-Fernandez, LA, Abad-Santos, F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3)DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3.400(Q3/6D).

Hentrich, MU, Bower, M, Daugaard, G, Dieing, A, Bickel, M, Berretta, M, Lesmeister, F, Jurinovic, V, Stoehr, A, Heinzelbecker, J, Krznaric, I, Dieckmann, KP, Necchi, A, Rey, PM, Rockstroh, JK, Brito, M, Pfister, D, Hoffmann, C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. CANCER. 2022; 128(2)DOI:10.1002/cncr.33928. PMID:34592009. IF:6.200(Q1/3D).

Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Carvajal, B, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara, M, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, dei Tos, AP, Malagon, HRD, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, David, BBL, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Perez, JMM, David, SM, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11.800(Q1/1D).

Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1)DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4.000(Q2/4D).

Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10.002(Q1/2D).

Cortellini, A, Ricciuti, B, Facchinetti, F, Alessi, JVM, Venkatraman, D, Dall'Olio, FG, Cravero, P, Vaz, VR, Ottaviani, D, Majem, M, Piedra, A, Sullivan, I, Lee, KA, Lamberti, G, Hussain, N, Clark, J, Bolina, A, Barba, A, Benitez, JC, Gorria, T, Mezquita, L, Hoton, D, Nana, FA, Besse, B, Awad, MM, Pinato, DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.08.1744. PMID:34400292. IF:51.769(Q1/1D).

Rofes, P, Gonzalez, S, Navarro, M, Moreno-Cabrera, JM, Solanes, A, Darder, E, Carrasco, E, Iglesias, S, Salinas, M, Gomez, C, Velasco, A, Tuset, N, Varela, M, Llort, G, Cajal, TRY, Grau, E, Duenas, N, Merlano, ND, Matias-Guiu, X, Rivera, B, Balmana, J, Pineda, M, Brunet, J, Capella, G, del Valle, J, Lazaro, C. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. JOURNAL OF MOLECULAR DIAGNOSTICS. 2021; 23(11)DOI:10.1016/j.jmoldx.2021.07.024. PMID:34454113. IF:5.341(Q1/3D).

Gronchi, A, Miah, AB, DeiTos, AP, Abecassis, N, Bajpai, J, Bauer, S, Biagini, R, Bielack, S, Blay, JY, Bolle, S, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Boye, K, Brennan, B, Brodowicz, T, Buonadonna, A, DeAlava, E, Del Muro, XG, Dufresne, A, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Frezza, AM, Gasperoni, S, Gelderblom, H, Gouin, F, Grignani, G, Haas, R, Hassan, AB, Hecker-Nolting, S, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Jungels, C, Jutte, P, Kager, L, Kasper, B, Kawai, A, Kopeckova, K, Krakorova, DA, Le Cesne, A, LeGrange, F, Legius, E, Leithner, A, Lopez-Pousa, A, Martin-Broto, J, Merimsky, O, Messiou, C, Mir, O, Montemurro, M, Morland, B, Morosi, C, Palmerini, E, Pantaleo, MA, Piana, R, Piperno-Neumann, S, Reichardt, P, Rutkowski, P, Safwat, AA, Sangalli, C, Sbaraglia, M, Scheipl, S, Schoffski, P, Sleijfer, S, Strauss, D, Strauss, S, SundbyHall, K, Trama, A, Unk, M, VandeSande, MAJ, VanderGraaf, WTA, van Houdt, WJ, Frebourg, T, Casali, PG, Stacchiotti, S, ESMO Guidelines Comm, EURACAN, GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.07.006. PMID:34303806. IF:51.769(Q1/1D).

Dabush, DR, Shepshelovich, D, Shochat, T, Tibau, A, Amir, E, Goldvaser, H. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. CANCER TREATMENT REVIEWS. 2021; 100DOI:10.1016/j.ctrv.2021.102293. PMID:34543860. IF:13.608(Q1/1D).

Casarrubios, M, Cruz-Bermudez, A, Nadal, E, Insa, A, Campelo, MDG, Lazaro, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, de Castro-Carpeno, J, Cobo, M, Lopez-Vivanco, G, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Barquin, M, Laza-Briviesca, R, Sierra-Rodero, B, Parra, ER, Sanchez-Espiridion, B, Rocha, P, Kadara, H, Wistuba, II, Romero, A, Calvo, V, Provencio, M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021; 27(21)DOI:10.1158/1078-0432.CCR-21-1200. PMID:34376534. IF:13.801(Q1/1D).

Wu, YL, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35)DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3.674(Q3/7D).

Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).

Riera, P, Paez, D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10)DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4.936(Q1/3D).

Herbst, RS, Garon, EB, Kim, DW, Cho, BC, Gervais, R, Perez-Gracia, JL, Han, JY, Majem, M, Forster, MD, Monnet, I, Novello, S, Gubens, MA, Boyer, M, Su, WC, Samkari, A, Jensen, EH, Kobie, J, Piperdi, B, Baas, P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Research in Social & Administrative Pharmacy. 2021; 16(10)DOI:10.1016/j.jtho.2021.05.001. PMID:34048946. IF:3.348(Q2/5D).

Ribelles, N, Alvarez-Lopez, I, Arcusa, A, Chacon, JI, de la Haba, J, Garcia-Corbacho, J, Garcia-Mata, J, Jara, C, Jerez, JM, Lazaro-Quintela, M, Leon-Mateos, L, Ramirez-Merino, N, Tibau, A, Garcia-Palomo, A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10)DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3.340(Q3/7D).

Riudavets, M, Sullivan, I, Abdayem, P, Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5)DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6.883(Q1/3D).